{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:19:36Z","timestamp":1776997176521,"version":"3.51.4"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,10,15]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Tumour necrosis factor-alpha (TNF-\u03b1) is a key proinflammatory cytokine in non-infective uveitis (NIU). Adalimumab, an anti-TNF-\u03b1 monoclonal antibody, is approved for the treatment of severe NIU by the European Medicines Agency. There is a recognised risk of serious infections, including tuberculosis (TB), during anti-TNF-\u03b1 therapy in systemic immune-mediated diseases. We describe miliary pulmonary TB during adalimumab therapy for severe NIU. To our knowledge, this is the first detailed report of this complication in a patient with uveitis. We present the challenges of managing vision-threatening uveitis during life-threatening infection necessitating withdrawal of adalimumab and oral immunosuppression therapy. Uveitis activity was controlled during anti-TB therapy with oral corticosteroid therapy.<\/jats:p>","DOI":"10.1136\/bcr-2018-226772","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e226772","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Miliary tuberculosis developing during adalimumab treatment for Beh\u00e7et\u2019s disease with uveitis"],"prefix":"10.1136","volume":"11","author":[{"given":"Minji Jennifer","family":"Kim","sequence":"first","affiliation":[{"name":"Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Jones","sequence":"additional","affiliation":[{"name":"Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura R","family":"Steeples","sequence":"additional","affiliation":[{"name":"Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"2025082711321294000_11.1.e226772.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"2025082711321294000_11.1.e226772.2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"2025082711321294000_11.1.e226772.3","unstructured":"European Medicines Agency. Humira. 2016 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000481\/smops\/Positive\/human_smop_000983.jsp&mid=WC0b01ac058001d127 (accessed 5 Jun 2018)."},{"key":"2025082711321294000_11.1.e226772.4","unstructured":"National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis. Technology appraisal guidance (TA460). 2018 https:\/\/www.nice.org.uk\/guidance\/ta460 (accessed 5 Jun 2018)."},{"key":"2025082711321294000_11.1.e226772.5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-Label Study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"2025082711321294000_11.1.e226772.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"2025082711321294000_11.1.e226772.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"2025082711321294000_11.1.e226772.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"2025082711321294000_11.1.e226772.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"issue":"sup1","key":"2025082711321294000_11.1.e226772.10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2025082711321294000_11.1.e226772.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"2025082711321294000_11.1.e226772.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq249a"},{"key":"2025082711321294000_11.1.e226772.13","unstructured":"Public Health England. Tuberculosis in England 2017 report (presenting data to end of 2016). https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/686185\/TB_Annual_Report_2017_v1.1.pdf (accessed 27 Sep 2018)."},{"key":"2025082711321294000_11.1.e226772.14","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.941919"},{"key":"2025082711321294000_11.1.e226772.15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/aos.12515","article-title":"Toxic optic neuropathies: an updated review","volume":"93","author":"Grzybowski","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"2025082711321294000_11.1.e226772.16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jamaophthalmol.2015.4092","article-title":"Oral fluoroquinolones and the risk of uveitis","volume":"134","author":"Sandhu","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2025082711321294000_11.1.e226772.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6369.923"},{"key":"2025082711321294000_11.1.e226772.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu041"},{"key":"2025082711321294000_11.1.e226772.19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00296-016-3575-3","article-title":"Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy","volume":"36","author":"Ozguler","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025082711321294000_11.1.e226772.20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/09273948.2016.1205633","article-title":"Sepsis during immunosuppression for sight-threatening uveitis: the flip side","volume":"26","author":"Jones","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2025082711321294000_11.1.e226772.21","doi-asserted-by":"crossref","unstructured":"Steeples LR , Anand N , Moraji J , et al . Clinical outcomes of intravitreal preservative-free triamcinolone preparation (triesence\u00ae) for cystoid macular oedema and inflammation in patients with uveitis. Ocul Immunol Inflamm 2017:1\u20138.doi:10.1080\/09273948.2017.1294185","DOI":"10.1080\/09273948.2017.1294185"},{"key":"2025082711321294000_11.1.e226772.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.09.003"},{"key":"2025082711321294000_11.1.e226772.23","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1111\/aos.13699","article-title":"Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review","volume":"96","author":"Leal","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"2025082711321294000_11.1.e226772.24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: A phase iii sirolimus study assessing double-masked Uveitis TReAtment (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"2025082711321294000_11.1.e226772.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2004.06.005"},{"key":"2025082711321294000_11.1.e226772.26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch Med Sci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-226772","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:32:19Z","timestamp":1756319539000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,4]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-226772"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226772","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}